Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection

J Infect Dis. 2017 Oct 17;216(7):819-823. doi: 10.1093/infdis/jix266.

Abstract

Persistent inflammation and immune activation have been associated with non-AIDS comorbidity and mortality in human immunodeficiency virus (HIV) infection. We aimed to investigate the potential association between soluble urokinase plasminogen activator receptor (suPAR) and incident non-AIDS comorbidity and all-cause mortality in a well-treated HIV-infected population. suPAR was measured by enzyme-linked immunosorbent assay, and events of comorbidity and mortality were ascertained by registry linkage. The study showed an independent association between a high suPAR level at baseline and increased hazard rates for both non-AIDS comorbidities (cardiovascular disease, chronic kidney disease, chronic lung disease, liver disease, and cancer) and all-cause mortality.

Keywords: HIV; comorbidity; inflammation; mortality; suPAR.

MeSH terms

  • CD4 Lymphocyte Count
  • Cohort Studies
  • HIV Infections / mortality*
  • HIV Infections / pathology*
  • Humans
  • Middle Aged
  • Multivariate Analysis
  • Predictive Value of Tests
  • Proportional Hazards Models
  • RNA, Viral / blood
  • Receptors, Urokinase Plasminogen Activator / genetics
  • Receptors, Urokinase Plasminogen Activator / metabolism*

Substances

  • RNA, Viral
  • Receptors, Urokinase Plasminogen Activator